CLINICAL TRIALS PROFILE FOR LORBRENA
✉ Email this page to a colleague
All Clinical Trials for LORBRENA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03737994 ↗ | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | Active, not recruiting | NRG Oncology | Phase 2 | 2019-04-01 | This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether a combination of biomarker/ALK inhibitors or chemotherapy may work better in treating patients with ALK positive non-squamous non-small cell lung cancer. |
| NCT03737994 ↗ | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2019-04-01 | This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether a combination of biomarker/ALK inhibitors or chemotherapy may work better in treating patients with ALK positive non-squamous non-small cell lung cancer. |
| NCT03878524 ↗ | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | Recruiting | Oregon Health and Science University | Phase 1 | 2020-04-01 | This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy. |
| NCT03878524 ↗ | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | Recruiting | Prospect Creek Foundation | Phase 1 | 2020-04-01 | This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy. |
| NCT03878524 ↗ | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | Recruiting | OHSU Knight Cancer Institute | Phase 1 | 2020-04-01 | This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy. |
| NCT04292119 ↗ | Lorlatinib Combinations in Lung Cancer | Recruiting | Array BioPharma | Phase 1/Phase 2 | 2020-05-01 | This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. - This research study involves four study drugs. - Lorlatinib - Binimetinib - Crizotinib - TNO155 |
| NCT04292119 ↗ | Lorlatinib Combinations in Lung Cancer | Recruiting | Pfizer | Phase 1/Phase 2 | 2020-05-01 | This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. - This research study involves four study drugs. - Lorlatinib - Binimetinib - Crizotinib - TNO155 |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LORBRENA
Condition Name
| Condition Name for LORBRENA | |
| Intervention | Trials |
| Lung Cancer | 2 |
| Metastatic Pancreatic Adenocarcinoma | 1 |
| Refractory Myelodysplastic/Myeloproliferative Neoplasm | 1 |
| Recurrent Acute Lymphoblastic Leukemia | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for LORBRENA
Trials by Country
Clinical Trial Progress for LORBRENA
Clinical Trial Phase
Clinical Trial Sponsors for LORBRENA
Sponsor Name
